ADVANCED CARE PLANNING (ACP) BEFORE STEM CELL TRANSPLANTATION (SCT) TREATMENT BEGINS

Neumann, J.L., Gallagher, C., Epner, D., Susan, G., Butrago, J., Richard, C. The University of Texas MD Anderson Cancer Center, Houston, TX

SCT is a high risk/reward proposition. Many experienced SCT practitioners perceive that SCT patients are not consistently prepared for the possibility of life threatening complications and poor outcomes. The SCT department was selected to pilot a patient-centered intervention to improve ACP discussions in our institution. ACP is an extraordinarily complex process, and many patient, provider, and system factors influence whether discussions occur.

Aim: Increase SCT patients’ awareness of the possibility of life threatening complications and poor outcomes by examining the number of advance directives (AD) and/or documentation of ACP conversations by at least 10%.

Interventions: A patient-centered educational initiative was developed. An existing admission class was enhanced by distributing a previously created ACP document. Salient points were discussed and patients were encouraged to talk to their providers prior to admission if they had any additional questions or concerns.

Results: A chart audit for documentation of ACP discussions and AD documents before (N = 32) and after (N = 35) the intervention was used. A patient survey was used to assess the patients’ response to ACP information presented in the class. Twelve (37%) AD documents were found before the intervention and 14 (40%) after. Documentation of the conversations between patients and providers (MD, PA, SW) occurred before the intervention and 31 (89%) after the intervention. Patient evaluations indicated the majority agreed or strongly agreed that this information was understandable, useful and prompted them to think about decisions and discussions they may need to have with family and care providers.

Conclusions: Because of the brief duration, we were unable to identify cost savings. However, based on improved understanding of ACP and patient-provider shared determinations of best patient-centered practice, further investigation is warranted which will include review of length of stay and changes in ICU usage and related cost savings. We have continued the intervention and are collecting additional data. Interventions will be modified as indicated, and we will continue to work on developing other metrics. Further, we plan to examine more specifically the meaning of a substantive conversation, leading to the development of trigger points for discussions. We ultimately expect to develop guidelines and training for providers, and continue to promote the importance of ACP.

INTEGRATING HSCT EVALUATION-PHASE ACTIVITIES TO REDUCE COST AND STREAMLINE WORKFLOW

Kostaras, P.M., Emmert, A.E. Dana-Farber/Brigham & Women’s Cancer Center, Boston, MA

The evaluation process required for insurance approval for HSCT occurs alongside the clinical work-up process which is in part governed by eligibility assessment standards set by FACT, the FDA, and other regulatory bodies. In a large academic cancer center, the functional differentiation among clinical staff, financial registrars and counselors, and transplant coordinators supporting patient case management during the evaluation phase for HSCT tends to generate separate standard work flows for each function, leading to inefficiency among staff and overuse of clinical testing. A workflow and decision tree analysis demonstrated an opportunity to create a single process engaging all coordination and clinical evaluation functions to reduce time to insurance approval, reduce overall effort for staff, reduce excess testing, and produce greater clarity and comfort for patients. Benefit review and documentation, testing requirements, hand-offs for appropriate peer to peer discussion and negotiation were all addressed as distinct processes that required optimized and integrated process improvement. The new workflow involves time point requirements and decision trees to ensure consistency and compliance. A focus on reducing non-critical or repeat testing generated a greater use of existing testing results and the education of payer case managers in FACT and cancer center eligibility standards effectively reduced requirements for early or up front testing that would need to be repeated prior to admission. Implementation revealed further opportunities for streamlining which were incorporated into the process. Outcomes show marked reduction/elimination of non-clinically valuable or duplicate testing, faster insurance authorization, and greater throughput relative to staffing levels.

ASSOCIATION AND REVISION OF PATIENT SCHEDULING FOR HSCT RELATED APHERESIS AND CELL PROCESSING TO REDUCE OVER-ALLOCATION AND UNDERUTILIZATION OF RESOURCES

King, B.S., Ellis, M., Sobert, D.M., Kostaras, P.M., Emmert, A.E. Dana-Farber/Brigham & Women’s Cancer Center, Boston, MA

With the initiation of the use of plerixafor and its impact on apheresis flow and utilization relative to HSCT in a large academic cancer center, resulting disruptive shifts in utilization prompted an evaluation of the scheduling processes supporting the clinical and product pathway from apheresis through processing and issuing of products for infusion. Several opportunities for improvement in communication, and distribution of work process across time periods were identified. An analysis of historical volume of